Lucier research receives Best Abstract recognition at CTRS 2026
Dr. Guangrong Lu presented Lucier's coronary microcirculation research at the 2026 Clinical and Translational Research Symposium, where the work received Best Abstract recognition.
Company announcement from Lucier Pharmaceuticals.
Dr. Guangrong Lu, Founder and CEO of Lucier Pharmaceuticals, presented an abstract at the 2026 Clinical and Translational Research Symposium, hosted by the University of Houston College of Pharmacy on May 22, 2026.
The abstract, “A novel molecular mechanism for coronary arteriolar constriction to endothelin-1 guides drug development to classify and treat coronary microvascular dysfunction,” was featured in both oral and poster formats. It received Best Abstract recognition in Target Identification & Drug Discovery.
Lucier appreciates the opportunity to share its scientific findings, potential drug candidates, and development strategy with the professional community. The company also recognizes the mentorship and collaboration of Professors Robert J. Widmer, Lih Kuo, and Travis W. Hein.
Lucier remains committed to advancing drug development for unmet medical needs and to strengthening academic partnerships across Texas.
Lucier's product candidates are investigational and in preclinical development. They have not been approved for patient use.